Novo Nordisk has announced a significant restructuring plan, involving the cutting of approximately 9,000 jobs, representing an 11% workforce reduction. This strategic pivot aligns with a sharpened focus on addressing market headwinds in the diabetes and obesity sectors amid increasing competition, notably from Eli Lilly. Concurrently, the company has requested its staff to return to full-time office work to enhance collaboration and decision-making as part of its revival efforts. These moves reflect Novo’s response to stalled sales growth and investor pressures impacting its market valuation.